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Background-—The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke
prevention in atrial fibrillation beyond warfarin, the main therapy for years. Little is known about their real-world comparative
effectiveness and safety, even less among patient demographic and clinical subgroups.
Methods and Results-—Using a cohort of non-valvular AF patients initiating anticoagulation from October 2010 to December 2012
drawn from a large US database of commercial and Medicare supplement claims, we applied propensity score weights to Cox
proportional hazards regression to assess the comparative effectiveness and safety of dabigatran versus warfarin. Analyses were
repeated among clinical and demographic subgroups using stratum-specific propensity scores as an exploratory analysis. Of the
64 935 patients initiating anticoagulation, 32.5% used dabigatran. Compared with warfarin, dabigatran was associated with a lower
risk of ischemic stroke or systemic embolism (composite adjusted Hazard Ratio [aHR], 95% CI: 0.86, 95% CI: 0.79 to 0.93),
hemorrhagic stroke (aHR: 0.51, 0.40 to 0.65), and acute myocardial infarction (aHR: 0.88, 95% CI: 0.77 to 0.99), and no relation
was seen between dabigatran and the composite harm outcome (aHR: 0.94, 95% CI: 0.87 to 1.01). However, dabigatran was
associated with a higher risk of gastrointestinal bleeding (aHR: 1.11, 95% CI: 1.02 to 1.22). Estimates of effectiveness and safety
appeared to be mostly similar across subgroups.
Conclusions-—Dabigatran could be a safe and potentially more effective alternative to warfarin in patients with atrial fibrillation
managed in routine practice settings. ( J Am Heart Assoc. 2015;4:e001798 doi: 10.1161/JAHA.115.001798)
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U sing anticoagulation in patients with atrial fibrillation(AF) is recommended to prevent stroke and systemic
embolism.1 Warfarin has been the only oral anticoagulant
available for the past few decades; however, warfarin has a
narrow therapeutic index that requires monitoring and has a
number of notable drug-drug and drug-food interactions.1
Recent availability of dabigatran, one of the novel oral
anticoagulants (NOACs), has provided an additional option
with some practical advantages including no currently
recommended routine blood monitoring requirements and
fewer interactions; however, dabigatran also lacks a conve-
nient agent to reverse bleeding.2,3
Despite similar or superior efficacy in the Randomized
Evaluation of Long Term Therapy (RE-LY) With Dabigatran
Etexilate trial used for Food and Drug Administration (FDA)
approval, the comparative effectiveness and safety of
dabigatran compared with warfarin is still unclear, particularly
in commercially insured individuals younger than 65 years of
age in real-world clinical practice.4 Even less is known about
the comparative clinical outcomes among important clinical
and demographic subgroups, particularly among subgroups
that may have been partly excluded in RE-LY, such as
patients with major renal insufficiency and recent, previous
stroke. In addition, the rates of adverse events submitted to
the FDA have also been higher for dabigatran compared with
warfarin since dabigatran’s market availability, but the FDA
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has since found no increased risk of adverse outcomes in a
large analysis of Medicare patients treated in clinical
practice.5,6
Therefore, we compared the effectiveness and safety of
dabigatran with warfarin in clinical practice among a large
nationally representative retrospective cohort of commer-
cially insured patients in the United States after availability of
the new oral anticoagulants, while also examining within
subgroups of patients with different underlying characteris-
tics. We sought to (1) assess the risk of ischemic stroke,
systemic embolism, acute myocardial infarction, or clinically
significant bleeding events among AF patients using dabiga-
tran compared with warfarin, and (2) explore the risk of these
same outcomes among strata of patients with clinically




We conducted a retrospective cohort study using the Truven
Health MarketScan Commercial Claims and Encounters and
Medicare supplement databases for the years 2009–2012.
These data files comprise patient-specific medical inpatient
and outpatient claims, physician office visits, outpatient
pharmaceutical data, and enrollment data for approximately
40 million individuals from over 100 nationwide employer-
provided plans annually. Prescription medication use was
identified through National Drug Codes (NDCs) in the
outpatient prescription files, including use of anticoagulation
therapies.
A cohort of patients with AF was selected from the
following inclusion criteria: (1) filling ≥1 prescription for
warfarin or dabigatran after 10/19/2010 (dabigatran FDA
approval date), hereafter referred to as the “index prescrip-
tion”; (2) ≥18 years of age at index prescription fill date; (3)
receiving at least 1 inpatient or 2 outpatient International
Classification of Diseases, ninth edition (ICD-9) codes for AF
(ICD-9: 427.31) occurring on separate days within
12 months before the index fill date; and (4) were contin-
uously enrolled for at least 12 months prior to the index fill
date. One of the outpatient ICD-9 AF codes could occur after
the index prescription fill date, but the 2 ICD-9 codes must
have occurred on separate days to eliminate the possibility
of the code being used as a rule-out condition. In addition,
patients were excluded from the study if they had an
anticoagulant prescription fill in the 12 months prior to the
index prescription fill to examine new users of anticoagula-
tion. Moreover, patients with ICD-9 codes related to valvular
or transient AF in the baseline period were excluded
(Table 1).
Outcome Measurements
Clinically important outcomes were measured in the follow-up
period after anticoagulant initiation. Clinical effectiveness was
defined as a composite of the occurrence of ischemic stroke,
TIA, and other thromboembolic events in the follow-up period.
Harm was defined as a composite of intracranial hemorrhage
or hemorrhagic stroke, gastrointestinal (GI) hemorrhage, or
other bleeding. Acute myocardial infarction was also assessed
as an outcome, but was not included in either of the clinical
effectiveness or harm composite outcomes. Outcomes were
assessed based on the presence of inpatient claims with
either a primary or secondary diagnosis. Validated ICD-9
coding algorithms were used to measure the outcome events,
which are based on published studies found in the literature
(Table 1).7–11 Patients were followed from the time of
anticoagulant initiation and continued until loss of continuous
eligibility, occurrence of a study outcome of interest, or end of
the administrative period (December 31, 2012).
Baseline Characteristics/Covariates
Patient demographic characteristics were identified in the 12-
month baseline based on their noted associations with
anticoagulant use and the clinical outcomes. Specific demo-
graphics included: age, census region of residence (northeast,
north central, south, west), type of health benefit plan
(comprehensive, health maintenance organization, point-of-
service, preferred provider organization, consumer-driven
health plan), gender, and a measure of the generosity of the
prescription drug benefit.12 Specifically, patients’ cost-sharing
proportions for all prescriptions in the 12 months prior to
anticoagulant initiation were divided by the total net drug
payments as a benefits’ generosity measure.12 This propor-
tion was categorized into 3 ratio levels that were paid by
patients: >0.80 (“No/Poor coverage”), 0.20 to 0.80 (“Fair
coverage), and ≤0.20 (“Good coverage”).
Patient comorbidities were also identified in the 12-month
baseline period using ICD-9 codes in the outpatient and
inpatient medical claims files based on previous litera-
ture.13–15 These comorbidities included previous ischemic
stroke, venous thromboembolism (VTE), congestive heart
failure (CHF), hypertension, hyperlipidemia, acute myocardial
infarction (AMI), coronary artery disease, bleeding, anemia,
peripheral vascular disease, renal impairment, anemia, diabe-
tes mellitus, peptic ulcer disease, dementia, and sleep apnea.
Clinical prediction risk scores, such as CHA2DS2-VASc score
(ischemic stroke risk), ATRIA score (bleeding risk), and the
Charlson Comorbidity index score, were also measured.13–15
Briefly, the CHA2DS2-VASc score incorporates congestive
heart failure, hypertension, age 65 to 74, age ≥75 years,
diabetes, prior ischemic stroke, female gender, coronary
artery disease and peripheral vascular disease and was
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categorized into the following 3 levels: 0 (low risk), 1
(intermediate risk), and ≥2 (high risk). The ATRIA score
includes anemia, severe renal disease, age ≥75 years,
previous hemorrhage and hypertension and was categorized
as follows: ≤3 (low risk), 4 (intermediate risk), and ≥5 (high
risk), conforming to previous standards. Of the bleeding
clinical prediction risk scores, the ATRIA score is considered
to be more reliably measured in secondary medical claims
compared with other bleeding risk indices.15–17 Concomitant
medication therapies were also measured because of known
associations with anticoagulation, including antiplatelet ther-
apies, gastroprotective agents, antiarrhythmics, rate control
therapies (eg, digoxin, beta-blockers, calcium channel block-
ers), and statins.
Statistical Analysis
Descriptive statistics were generated including the outcome
rates per 1000 person years in each anticoagulant group and
distributions of baseline characteristics. The absolute stan-
dardized difference was also used to compare the baseline
characteristics between warfarin and dabigatran users,
whereby significant imbalance of baseline characteristics
between groups is usually characterized by an absolute
standardized difference >10.18
We estimated adjusted hazard ratios (aHRs) and 95%
confidence intervals (CIs) using Cox proportional hazards
regression models with stabilized inverse probability treat-
ment weighting (IPTW).19 These propensity score weights
were estimated using logistic regression that included all
variables in Table 2 as covariates. The propensity score
distributions were examined by exposure status for overlap to
assess factors associated with overall treatment selection and
comparability of the covariate distributions. We then esti-
mated the treatment effects using propensity score weighting,
including IPTW approaches, trimming for non-overlapping
regions.19 The estimated weights were incorporated into the
Cox regression models that only included the anticoagulant
treatment variable. Various sensitivity analyses were con-
ducted in which we varied the outcome definitions and how
the propensity score was used. These were repeated analyses
that included outcomes occurring in the outpatient setting,
examining patients who lost continuous eligibility, stratifying
by type of beneficiary (commercially insured or Medicare
supplement), and restricting to patients with newly diagnosed
AF. We also examined the proportion of patients with
in-hospital death that was observed in the patients’ hospital
discharge statuses.
We repeated these analyses among subgroups of patients
with demographic and clinical characteristics that may
Table 1. Coding Schematics for Exclusion Criteria and Outcome Definitions
Outcome ICD-9 Codes Diagnosis Position
Exclusion criteria
Liver disease 571.1, 571.3, 571.5, 571.8, 571.9, 572.8, 573.3, 573.9 Any
Coagulation deficiency 269.0, 286.0 to 286.8, 286.52, 286.53, 286.59 Any
Mitral valve replacement 35, 37, 35.1, 35.2, 35.9, 35.12, 35.23, 35.24, 35.9,
35.96, 35.97, 37.4, 37.35, 37.4, 37.41
Any
Heart valve replacement V42.2, V43.3 Any
Mitral stenosis 394.0, 394.2, 396.0, 396.1, 396.8 Any
Atrial flutter 427.32 Any
Hyperthyroidism 242, 242.0, 242.1, 242.2, 242.3, 242.9 Any
Clinical effectiveness outcomes
Ischemic stroke 433.01, 433.11, 433.21, 433.31, 433.81, 433.91,
434 (excluding 434.x0), 436
Primary or secondary
Transient ischemic attack 435 Primary




430, 431, 432 Primary or secondary
Gastrointestinal hemorrhage 455.2, 455.5, 455.8, 456.0, 456.20, 459.0, 530.82, 578 Any
Other bleeding events 423.0, 593.81, 599.7, 719.11, 784.7, 784.8, 786.3 Any
Acute myocardial infarction 410.x1 Primary or secondary
DVT indicates deep vein thrombosis; PE, pulmonary embolism.
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Table 2. Baseline Characteristics of Patients With AF Initiating Anticoagulation, 2010–2012
Baseline Characteristic Warfarin, N (%) Dabigatran, N (%) Absolute SD
Demographic
Age, y
<55 3886 (8.9) 2963 (14.1) 20.2
55 to 64 10 146 (23.1) 6443 (30.6) 20.5
65 to 74 9792 (22.3) 4838 (23.0) 2.1
≥75 20 041 (45.7) 6826 (32.4) 34.3
Mean (standard deviation) 71.4 (12.2) 67.5 (12.4)
Male gender 25 562 (58.3) 13 363 (63.4) 11.6
Region
Northeast 7589 (17.3) 3513 (16.7) 2.1
North central 15 408 (35.1) 6107 (29.0) 15.7
South 12 181 (27.8) 7864 (37.3) 26.1
West 7732 (17.6) 3259 (15.5) 7.2
Insurance plan
Comprehensive 15 701 (35.8) 6812 (32.3) 8.9
HMO 6368 (14.5) 1723 (8.2) 24.3
POS 1973 (4.5) 1226 (5.8) 8.6
PPO 16 889 (38.5) 9766 (46.4) 19.4
CDHP 707 (1.6) 464 (2.2) 6.7
Good benefits’ generosity (≤0.20) 19 595 (44.7) 10 611 (50.4) 13.5
Clinical
Ischemic stroke 4710 (10.7) 1495 (7.1) 18.9
Congestive heart failure 12 414 (28.3) 3851 (18.3) 32.7
Venous thromboembolism 5385 (12.3) 538 (2.6) 81.8
Hyperlipidemia 21 710 (49.5) 10 456 (49.6) 0.2
Hypertension 32 043 (73.0) 14 578 (69.2) 9.1
Myocardial infarction 2001 (4.6) 500 (2.4) 19.9
Coronary artery disease 15 000 (34.2) 5942 (28.2) 16.5
Peripheral vascular disease 3892 (8.9) 1150 (5.5) 20.2
Renal impairment 5517 (12.6) 1210 (5.7) 39.8
Diabetes 13 957 (31.8) 5610 (26.6) 14.6
Bleeding 5975 (13.6) 1983 (9.4) 19.1
Anemia 8736 (19.9) 2241 (10.6) 39.4
Peptic ulcer disease 320 (0.7) 93 (0.4) 6.7
Sleep apnea 4546 (10.4) 2526 (12.0) 6.6
Cognitive deficiency 438 (1.0) 126 (0.6) 7.3
Hospitalizations (≥1) 4710 (10.7) 1495 (7.1) 18.9
Catheter ablation 12 414 (28.3) 3851 (18.3) 32.7
CCI
0 10 051 (22.9) 7091 (33.7) 28.7
1 to 2 17 657 (40.3) 9058 (43.0) 6.5
Continued
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influence treatment selection and effects as exploratory
analyses. The propensity score was re-estimated within each
subgroup in the regression models. These demographic
subgroups were gender groups, age groups, and patients
with different prescription benefits’ generosity levels, and the
clinical subgroups included patients with previous ischemic
stroke, VTE, CHF, AMI, renal insufficiency, and diabetes.
Lastly, strata of patients with different ATRIA and CHA2DS2-
VASc scores were also examined.
Statistical significance was determined using 2-sided tests
with alpha=0.05. All analyses were conducted using SAS 9.3
(Cary, NC). The University of North Carolina at Chapel Hill
Institutional Review Board reviewed this study, and it received
exempt approval status.
Results
In total, 64 935 AF patients met study criteria, with 21 070
(32.5%) using dabigatran and 43 865 (67.5%) using warfarin
(Figure 1). The mean age of the cohort was 69.9 years
(standard deviation [SD] 12.4), and 42 334 (60.1%) were male.
Measured baseline demographic and clinical characteristics of
the AF patients are provided in Table 2. Newusers of dabigatran
weremore likely to be younger,male, from the South region, use
high-deductible health or preferred provider organization
insurance health plans, and have good prescription benefits
coverage (ratio ≥0 and ≤0.20) for medications filled within the
previous 12 months. Patients using warfarin for the first time
were more likely to have experienced relevant comorbidities,
particularly ischemic stroke, CHF, and VTE.
The estimated densities of the propensity scores are
shown in Figure 2A. After examining the individual covariates,
the ones most contributing to the slight non-overlap seen in
the warfarin group were the baseline prescription benefits’
generosity and venous thromboembolism covariates, despite
their association with both exposure and outcomes
(Figure 2B). These characteristics were examined further in
stratum-specific estimates and sensitivity analyses. However,
Table 2. Continued
Baseline Characteristic Warfarin, N (%) Dabigatran, N (%) Absolute SD
3 to 5 11 871 (27.1) 4001 (19.0) 26.2
6 to 8 3165 (7.2) 686 (3.3) 29.9
≥9 1121 (2.6) 234 (1.1) 20.1
CHA2DS2-VASc score
0 2182 (5.0) 1881 (8.9) 24.3
1 5121 (11.7) 3981 (18.9) 29.2
≥2 36 562 (83.4) 15 208 (72.2) 28.6
Mean (standard deviation) 2.9 (1.7) 2.3 (1.6)
ATRIA score
0 to 3 30 667 (69.9) 17 602 (83.5) 65.8
4 4158 (9.5) 1501 (7.1) 12.6
≥5 9040 (20.6) 1967 (9.3) 50.6
Mean (standard deviation) 2.9 (2.4) 2.0 (1.9)
Medication use
Antiplatelet therapy* 5726 (13.1) 2684 (12.7) 1.6
Gastroprotective agent 5558 (12.7) 2267 (10.8) 8.2
Antiarrhythmic 9991 (22.8) 5344 (25.4) 7.6
Digoxin 7435 (16.9) 2973 (14.1) 10.5
Beta-blocker 29 513 (67.3) 14 132 (67.1) 0.5
Calcium channel blocker 18 501 (42.2) 8602 (40.8) 3.4
ACEI/ARB 25 001 (57.0) 11 891 (56.4) 1.4
Statin 23 964 (54.6) 11 205 (53.2) 3.2
Hormone 1626 (3.7) 959 (4.6) 6.0
ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CCI, Charlson Comorbidity Index; CDHP, consumer-driven health plan;
HMO, health maintenance organization; POS, Point-of-service; PPO, preferred provider organization; SD, standardized difference.
*Antiplatelet therapy measurement did not include aspirin due to data availability.
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the c-statistic for the main propensity score was 0.69,
indicating a good fit, and there was a high degree of overlap.
There was also no imbalance in covariates after propensity
score weighting (Table 3).
The mean patient follow-up time from initiation was
358 days (SD 224 days). Table 4 shows the comparative
effectiveness and harm outcomes among all anticoagulant
initiators, including unadjusted outcome rates. In the warfarin
group, there were 48.6 effectiveness composite events per
1000 person years compared with 30.2 events per 1000
person years in the dabigatran group. The outcome rate for
the harm composite was 51.6 events per 1000 person years
and 31.8 events per 1000 person years in the warfarin and
dabigatran groups, respectively.
The PS-adjusted HR of the effectiveness composite for
dabigatran users compared with warfarin was 0.86 (95% CI:
0.79 to 0.93). For the harm composite, the aHR for users of
dabigatran compared with warfarin was (aHR: 0.94, 95% CI:
0.87 to 1.01). Using dabigatran compared with warfarin was
associated with a 12% reduction in the hazard of experiencing
AMI (aHR: 0.88, 95% CI: 0.77 to 0.99). Initiating dabigatran
also resulted in a statistically significant reduction in the
hazard of VTE (aHR: 0.70, 95% CI 0.60 to 0.80), hemorrhagic
stroke (aHR: 0.51, 95% CI: 0.40 to 0.65), and other bleeding
(aHR: 0.76, 96% CI: 0.65 to 0.89) compared with warfarin
initiation. However, dabigatran was also associated with an
increased hazard of GI hemorrhage (aHR: 1.11, 95% CI: 1.02
to 1.22). The PS-adjusted survival curves between dabigatran
and warfarin users for experiencing the effectiveness com-
posite, harm composite, and AMI are shown in Figure 3. Other
sensitivity analyses are shown in Table 5 and yielded similar
associations with slightly differing magnitudes, but the overall
conclusions were robust to these modifications. Of the
14 219 warfarin patients hospitalized in the follow-up period
after initiation, 381 (2.7%) were coded as “Died” or “Other
died status” upon discharge; by contrast, of the 5932
dabigatran patients hospitalized in the follow-up, 95 (1.6%)
were similarly coded.
Table 6 shows the estimated comparative effectiveness
and safety among the examined subgroups after propensity
score adjustment using stratum-specific weighting and forest
plots of the aHRs and 95% CIs. The estimates of effectiveness
compared with the original HR appeared to be similar across
subgroups; the magnitudes appeared to be slightly stronger in
some subgroups. Compared with the original HR, most of the
adjusted HRs showed no relation between dabigatran use and
an increased or decreased risk of harm outcomes. Compared
with warfarin users, male patients, patients <55 years of age
or 55 to 64 years of age, and patients with low or
intermediate bleeding risk appeared to possibly have a
decreased risk of a harm outcome using dabigatran. Lastly,
compared with the original HR, the slight protective associ-
ation against the risk of AMI using dabigatran compared with
warfarin persisted in many subgroups; however, due to wide
95% CIs resulting from a small number of outcomes, no
significant relation was also seen in some groups.
Figure 1. Cohort schematic of new dabigatran or warfarin users
in patients with atrial fibrillation.
A
B
Figure 2. Estimated propensity score kernel densities among
new users of dabigatran and warfarin.
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Table 3. Balance of Covariates After Applying the IPTW Propensity Scores Among Users of Dabigatran and Warfarin
Baseline Characteristic Warfarin, % Dabigatran, % Absolute SD
Demographic
Age, y
<55 10.5% 10.2% 1.3
55 to 64 25.6% 25.3% 0.9
65 to 74 22.5% 22.8% 0.9
≥75 41.4% 41.8% 1.0
Male gender 59.9% 59.2% 1.6
Region
Northeast 16.7% 17.3% 2.1
North Central 33.1% 33.0% 0.3
South 31.0% 31.1% 0.3
West 16.9% 17.2% 1.0
Insurance plan
Comprehensive 34.4% 35.6% 2.4
HMO 12.4% 11.8% 0.6
POS 4.9% 4.8% 1.5
PPO 41.1% 41.7% 1.2
CDHP 1.8% 1.8% 0.0
Good benefits’ generosity (≤0.20) 46.5% 46.0% 1.2
Clinical
Ischemic stroke 9.6% 10.1% 2.3
Congestive heart failure 25.1% 26.4% 3.8
VTE 9.1% 10.5% 6.6
Hyperlipidemia 49.6% 50.1% 1.2
Hypertension 71.9% 72.5% 1.2
Myocardial infarction 3.9% 3.9% 0.0
Coronary artery disease 32.3% 33.1% 2.1
Peripheral vascular disease 7.8% 8.6% 4.0
Renal impairment 10.4% 11.2% 3.5
Diabetes 30.1% 30.7% 1.6
Bleeding 12.3% 13.0% 2.8
Anemia 16.9% 17.7% 2.8
Peptic ulcer disease 0.6% 0.7% 1.8
Sleep apnea 11.0% 11.5% 2.1
Cognitive deficiency 0.9% 1.0% 1.5
≥1 hospitalizations 53.4% 53.7% 0.7
Catheter ablation 1.3% 1.3% 0.0
CCI
0 26.3% 25.6% 2.0
1 to 2 41.2% 40.3% 2.2
3 to 5 24.5% 25.2% 2.1
Continued
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In this large cohort study of 64 935 AF patients, we examined
the comparative effectiveness and safety of patients initiating
warfarin or dabigatran for stroke prevention. We found a
consistent decreased risk of systemic embolism, ischemic
stroke, and AMI in patients using dabigatran compared with
warfarin and did not find evidence of an increased risk of
Table 3. Continued
Baseline Characteristic Warfarin, % Dabigatran, % Absolute SD
6 to 8 5.9% 6.6% 4.1
≥9 2.1% 2.3% 2.0
CHA2DS2-VASc score
0 6.2% 6.0% 1.1
1 14.0% 13.7% 1.1
≥2 79.7% 80.3% 1.6
ATRIA score
0 to 3 74.3% 73.2% 2.7
4 8.7% 8.9% 1.0
≥5 17.0% 17.9% 3.1
Medication use
Antiplatelet therapy* 13.0% 13.4% 0.7
Gastroprotective agent 12.0% 11.8% 0.8
Antiarrhythmic 23.7% 23.9% 0.6
Digoxin 16.1% 16.8% 2.5
Beta-blocker 67.2% 67.9% 1.6
Calcium channel blocker 41.8% 42.5% 1.7
ACEI/ARB 56.9% 57.5% 1.4
Statin 54.2% 54.7% 1.1
ACEI indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson Comorbidity Index; CDHP, consumer-driven health plan; HMO, health maintenance
organization; IPTW, inverse probability treatment weighting; POS, point-of-service; PPO, preferred provider organization; SD, standardized difference; VTE, venous thromboembolism.
*Antiplatelet therapy measurement did not include aspirin due to data availability.
Table 4. Estimated Treatment Effects in Patients With AF Using Dabigatran Compared With Warfarin
Outcome Type Warfarin Events/1000 Person-Years Dabigatran Events/1000 Person-Years Unadjusted HR (95% CI) Adjusted (PS-IPTW) HR (95% CI)
Effectiveness
Composite 48.6 30.2 0.62 (0.57 to 0.68)** 0.86 (0.79 to 0.93)**
Ischemic stroke 35.6 17.3 0.74 (0.70 to 0.79)** 0.91 (0.81 to 1.02)
TIA 11.3 9.2 0.83 (0.70 to 0.97)* 1.07 (0.91 to 1.25)
VTE 20.4 9.1 0.45 (0.38 to 0.52)** 0.70 (0.60 to 0.80)**
Safety
Composite 51.6 31.8 0.61 (0.56 to 0.67)** 0.94 (0.87 to 1.01)
Hemorrhagic stroke 8.0 3.3 0.41 (0.31 to 0.53)** 0.51 (0.40 to 0.65)**
GI hemorrhage 32.1 21.8 0.68 (0.61 to 0.75)** 1.11 (1.02 to 1.22)*
Other bleeding 14.4 8.1 0.56 (0.48 to 0.67)** 0.76 (0.65 to 0.89)**
AMI 19.1 13.1 0.66 (0.57-.0.76)** 0.88 (0.77 to 0.99)*
AF indicates atrial fibrillation; AMI, acute myocardial infarction; GI, gastrointestinal; HR, hazard ratio; IPTW, inverse probability treatment weighting; PS, Propensity score; TIA, transient
ischemic attack; VTE, venous thromboembolism.
*P<0.05; **P<0.001.
DOI: 10.1161/JAHA.115.001798 Journal of the American Heart Association 8















harm outcomes with the exception of GI hemorrhage. In the
exploratory analyses, with a few exceptions, dabigatran did
not appear to increase the risk of outcomes across the
subgroups. AMI risk also did not appear to differ drastically
among subgroups, largely due to wide 95% CIs resulting from
a small number of outcomes. However, these subgroup
analyses should be interpreted with much caution as they
were exploratory and intended for hypothesis generation in
future research.
Until recently, previous studies examining the comparative
effectiveness and safety of dabigatran versus warfarin have
mainly drawn from the RE-LY study used for FDA approval and
meta-analyses including the other studied NOACs.3,20,21 The
meta-analyses broadly found dabigatran to have similar or
better efficacy in preventing ischemic stroke and systemic
embolism compared with warfarin but significantly better
safety, particularly in reducing intracranial bleeding and
hemorrhagic stroke.3,4,22 In a large study of Medicare
patients, Graham et al found that dabigatran was associated
with a lower risk of ischemic stroke, intracranial hemorrhage
and death, and increased risk of major GI hemorrhage
compared with warfarin. Hernandez et al found that dabiga-
tran was associated with a higher risk of major bleeding and
GI bleeding with a lower risk of intracranial hemorrhage in a
smaller subset of Medicare patients. A few other studies in
real-world clinical practice have either been conducted in
Europe or included small sample sizes, and these have shown
similar results as our study.23–25 A recent report by the FDA of
a very large cohort of Medicare patients with atrial fibrillation
found similar associations with lower risk of clot-related
strokes, intracranial bleeding, and death compared with
warfarin.26 Overall, some controversy surrounding the relative
bleeding rates between dabigatran and warfarin still exists
and more research is warranted.
The results of our study are consistent with most previous
results in that we have found that dabigatran appears to be
more effective than warfarin in preventing ischemic stroke
and systemic embolism. Unlike the RE-LY trial, where
patients were subject to regular follow-up dictated by a
study protocol, in our study, these were patients in real-world
practice. Indeed, our study’s absolute event rates for
ischemic stroke or systemic embolism were approximately
twice the event rates in the RE-LY study. However, this is
expected, as we included a wider population of patients
managed in real-world practice with non-valvular AF, as
reflected by the relatively higher mean ischemic stroke risk
scores. Just as in the RE-LY trial, GI bleeding was also higher
among dabigatran patients compared with warfarin patients
in our study, but overall, there were otherwise no general
differences in the risk of harm or adverse outcomes.
Compared with the recent studies in the Medicare population
by Graham et al and Hernandez et al, while we examined
commercially insured patients, we found similar increased
risks of GI hemorrhage as in both of these studies and lower
risk of ischemic stroke as in the study by Graham et al.6,27
Our study found no difference in the risks of major bleeding
between the 2 groups, but a lower risk of hemorrhagic stroke,
which was slightly different than these 2 studies. In these
studies, Graham et al found a decreased risk of all types of
bleeding except for GI, and Hernandez et al found an
increased risk in all but intracranial hemorrhage.6,27 In
addition to population differences, there were also some
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Figure 3. Adjusted survival curves of dabigatran and warfarin
users and the risk of an effectiveness composite outcome, a
safety composite outcome, and acute myocardial infarction.
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Our study also explored the effects of anticoagulation
among patient subgroups. Among the pre-specified clinically
relevant demographic and clinical subgroups, the effects
were similar to those observed in the full cohort, although
there was some possible variation among the sub-groups.
Moreover, we noted with some potential concern that our
estimates trended towards a possible increased risk of
adverse outcomes among women using dabigatran com-
pared with warfarin. Previous research has indicated that
women may benefit from more aggressive anticoagulation
than men, and our results could reflect these conclusions.28
The fact that dabigatran did not appear to increase the risk
of experiencing one of the composite outcomes in almost
all of the sensitivity analyses and subgroup analyses
may be reassuring. Perhaps some residual unmeasured
confounding could provide an explanation for any differ-
ences noted. Further research is warranted to continue to
explore potential areas of heterogeneity in treatment effects
among patient subgroups, and we strongly caution against
overinterpretation of the estimates as these exploratory
analyses were intended to be used for hypothesis gener-
ation only.
Our study has several limitations. First, this is an
observational study, and despite adjusting for a wide range
of comorbidities, some residual confounding is likely because
of unmeasured or inadequately measured confounders.29–31
Because patients at higher risk of stroke or bleeding were
more likely to use warfarin, covariate adjustment moved the
estimate closer to the null than the unadjusted estimate, and
unmeasured confounding could overestimate the benefit and
underestimate the harms from dabigatran.32 Renal insuffi-
ciency was measured using claims, because creatinine
clearance was not available in the database. AF duration
was also unavailable. Refill records from commercial claims
databases may also not fully reflect medication use. Patients
may not take medications as filled and also may fill
prescriptions outside of their pharmacy benefit; thus, some
of the new users may be continuing users, and some may not
be taking their medication.33,34 However, refill records are
generally a widely accepted means of assessing medication
exposure and have been shown to have good validity,
correlation, and similar sensitivity and specificity with other
measurements, including self-report, pill counts, and elec-
tronic records.35,36
In addition, information about mortality is also not available
in the database, which may have biased the survival analysis.
This limitation was explored by including patients who lost
continuous eligibility in the outcome definition (which could
possibly have been a consequence of dying), and while the
estimates moved much closer to the null, the overall direction
of the estimates remained similar. In-hospital deaths were
also examined, and there was a higher proportion in the
warfarin group. We also could not account for site-level
variance due to data limitations. Lastly, because over-the-
counter medication use was not available in the database, we
could not measure concomitant aspirin use.
There are several strengths of this study. This research
used a large database of nationally representative commer-
cially insured patients, including some Medicare beneficiaries.
Moreover, most previous research outside the original clinical
trials to our knowledge examining the use of the novel
anticoagulants, particularly in younger patients, has been
conducted in Europe or in smaller databases. This study also
examined effectiveness and safety >2 years after dabigatran
became available and among patient demographic and clinical
subgroups.
Conclusion
Our retrospective cohort study suggests that dabigatran could
be equally safe and possibly more effective than warfarin in
commercially insured patients in clinical practice.
Table 5. Sensitivity Analyses of Estimated Treatment Effects in AF Patients Using Dabigatran Compared With Warfarin
Outcome Type
Effectiveness Composite
PS-IPTW HR (95% CI)
Safety Composite
PS-IPTW HR (95% CI) AMI Outcome PS-IPTW HR (95% CI)
Original results 0.86 (0.79 to 0.93)** 0.94 (0.87 to 1.01) 0.88 (0.77 to 0.99)*
1. Exclude VTE and prescription benefits’ generosity from PS 0.81 (0.74 to 0.88)** 0.81 (0.75 to 0.88)** 0.90 (0.79 to 1.03)
2. Restrict to newly-diagnosed AF 0.83 (0.74 to 0.94)* 0.79 (0.71 to 0.89)** 0.85 (0.71 to 1.01)
3. Restrict to commercially-insured patients 0.70 (0.59 to 0.83)** 0.74 (0.63 to 0.88)** 0.76 (0.58 to 0.99)*
4. Restrict to medicare supplemental patients 0.88 (0.79 to 0.97) 0.85 (0.77 to 0.94)* 0.88 (0.75 to 1.03)
5. Include outpatient ICD-9 codes (same diagnosis positions) 0.70 (0.67 to 0.74)** 1.02 (0.99 to 1.05) N/A
6. Include patients who lost continuous eligibility in outcome definition 0.92 (0.89 to 0.96)** 0.97 (0.94 to 0.99)** 0.90 (0.79 to 1.03)
AF indicates atrial fibrillation; HR, hazard ratio; PS, propensity score; IPTW, inverse probability treatment weighting; AMI, acute myocardial infarction; VTE, venous thromboembolism; TIA,
transient ischemic attack; ICD, international classification of disease.
*P<0.05; **P<0.001.
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